Insmed (INSM) Stock Forecast & Price Target

Insmed is viewed positively because its two commercial respiratory products are already showing meaningful U.S. traction, with Brinsupri’s 2Q26 revenue of $309.2M and FY2026 guidance of $1.25B-$1.4B signaling strong launch execution, while Arikayce’s FY2026 revenue remains guided at $450M-$470M and was supported by higher-than-expected ex-U.S. sales. The outlook is further strengthened by an expanding treatable population, improved payer approval and compliance trends, and favorable gross-to-net expectations for Brinsupri, which help offset the pause in Europe and support durable U.S. growth. Longer term, TPIP adds substantial pipeline value, with positive Phase 2 data, a once-daily profile versus Tyvaso’s four-times-daily dosing, and risk-adjusted peak sales around $4.9 billion, reinforcing the company’s multi-asset growth story.

Insmed is facing a weaker fundamental setup because operating expenses are rising sharply ahead of four launches, with 2027 R&D lifted to $1,022M and SG&A to $1,133M, while 2027E EPS falls to $1.24 from $3.26 on roughly $531M less operating income. The model also implies margin pressure, as 2034 operating margin drops to 62.8% from 69.6% due to three respiratory products sharing one call point, outsourced manufacturing, and Brinsupri’s tiered royalty to AstraZeneca. Beyond that, cash taxes begin in FY27E, liabilities are being paid down, and with ~$1.2Bn of cash at the end of 2Q 2026, the stock still faces meaningful execution risk from Brinsupri persistence, frontline Arikayce, and TPIP Phase 3 programs.